News

Under terms of the Agreement, Axella will contribute over $1m in funding and the delivery of key clinical research organization (CRO) services, including the management and execution of

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. The open label Phase IIa study (the

The milestone stems from Sanofi’s decision to continue advancing the tetraspecific Anticalin-based program for infectious disease. The drug candidate selectively binds four classes of siderophores produced by Pseudomonas

The strategic move between Takeda, an R&D driven pharmaceutical company which has a long history as a leading company in Japan, and Teva, among the top ten pharmaceutical

The approval of this first and only immunostimulatory antibody for multiple myeloma is based on data from the randomized, open-label, Phase 3, ELOQUENT-2 study, which demonstrated that the

A biologics license application (BLA) was submitted to the US Food and Drug Administration (FDA), while a Grouped Type II variation/extension application was filed with the European Medicines

CGS-200 is a novel high-strength topical formulation of the TRPV1 channel agonist trans-capsaicin combined with hyaluronic acid. It has been designed to deliver long-term desensitization of nerve fibers

The approval, which authorizes the sale of the product in all 28 member states of the European Union, follows the positive opinion from the European Medicines Agency’s Committee

Under the collaboration, the companies will research and develop potential new medicines directed at about 10 GPCR targets. Heptares will apply its GPCR structure-guided platform to help offer